Oncolytic Viruses: Therapeutics With an Identity Crisis
نویسندگان
چکیده
منابع مشابه
Oncolytic Viruses: Therapeutics With an Identity Crisis
Oncolytic viruses (OV) are replicating viral therapeutics for the treatment of cancer and have been in laboratory development for about twenty years. Recently, the FDA approved Imlygic, a herpes virus based therapeutic for the treatment of melanoma and thus OVs have entered a new era where they are a weapon in the armament of the oncologist. OVs are unique therapeutics with multiple mechanisms ...
متن کاملOncolytic Viruses
1Genelux Corporation, San Diego Science Center, San Diego, CA 92019, USA 2Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, CA 92093, USA 3Department of Biochemistry, University of Wuerzburg, 97074 Wuerzburg, Germany 4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, 97078 Wuerzburg, Germany 5 I...
متن کاملOncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics
INTRODUCTION The meeting opened with a lecture by OV pioneer and Golden Virus Award recipient Robert Martuza (Massachusetts General Hospital, Boston, MA), who discussed the interplay between bench and bedside and the importance of good communication between the two to drive the field. He emphasized the aspects that all tumors have in common and the key role of basic research in designing vector...
متن کاملIdentity crisis?
This article responds to arguments made in a recent paper by Bucholtz and Hall (Bucholtz, M., Hall, K., 2004. Theorizing identity in language and sexuality research. Language in Society 33, 469–515), in which two contrasting approaches to language and sexuality, dubbed ‘‘identity-based’’ and ‘‘desire-centered’’, are identified, and the latter is critiqued. As well as seeking to correct some ina...
متن کاملDesigning and building oncolytic viruses
Oncolytic viruses (OVs) are engineered and/or evolved to propagate selectively in cancerous tissues. They have a dual mechanism of action; direct killing of infected cancer cells cross-primes anticancer immunity to boost the killing of uninfected cancer cells. The goal of the field is to develop OVs that are easily manufactured, efficiently delivered to disseminated sites of cancer growth, unde...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: EBioMedicine
سال: 2016
ISSN: 2352-3964
DOI: 10.1016/j.ebiom.2016.06.046